Sf Therapeutics Cooperative Inc is categorized under Biotherapeutics in San Francisco, CA and active since 2011.
Sf Therapeutics Cooperative Inc was established in 2011, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Biotherapeutics business, which does work in the BOTH market, and is classified as a Biotherapeutics, under code number 424210 by the NAICS.
If you are seeking more information, feel free to contact Eric Chun at the company’s single location by writing to 1859 Page St Apartment 2, San Francisco, California CA 94117 or by phoning (415) 702-9932. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Sf Therapeutics Cooperative Inc |
| Contact Person: | Eric Chun |
| Address: | 1859 Page St Apartment 2, San Francisco, California 94117 |
| Phone Number: | (415) 702-9932 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2011 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B & B2C |
| Business Category: | Biotherapeutics |
| SIC Code: | 5122 |
| NAICS Code: | 424210 |
| Share This Business: |
Sf Therapeutics Cooperative Inc was started in 2011 to provide professional Biotherapeutics under the SIC code 5122 and NAICS code 424210. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Eric Chun for inquiries that concern Sf Therapeutics Cooperative Inc by calling the company number (415) 702-9932, as your correspondence is most welcome. Additionally, the physical location of the single location of Sf Therapeutics Cooperative Inc can be found at the coordinates 37.770239,-122.451501 as well as the street address 1859 Page St Apartment 2 in San Francisco, California 94117.
For its online presence, you may visit Sf Therapeutics Cooperative Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.